Moderna Inc. 2026年季度报告

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ As of April24, 2026, there were 396,786,259 shares of the registrant’s common stock, par value $0.0001 per share, outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Form 10-Q) contains express or implied forward-looking statements. All statements other thanthose of historical facts contained in this Form 10-Q are based on our management’s beliefs and assumptions and on information •our ability to drive use of our commercial products and expectations regarding a return to sales growth in 2026; •our ability to execute on our prioritized research and development portfolio; •our ability to deliver cost efficiency across our business; •our expectations regarding the size and durability of the respiratory vaccine market; •the availability of mCOMBRIAX across the EU, subject to national regulatory and access procedures; •our long-term strategic partnerships with government entities; •anticipated near-term regulatory actions for our product candidates, including potential filings, reviews and approvals; •anticipated milestones for our pipeline programs, including potential data readouts and other near-term catalysts; •our ability to obtain and maintain regulatory approval of our product candidates across our portfolio; •our ability to successfully launch and commercialize our products and the timing of launches; •the potential of our oncology portfolio; •our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute ourcommercial products and any future commercial products at scale, as well as drug substances, delivery vehicles, development •financing and funding options we may consider as part of our research and development strategy; •our ability to successfully contract with third-party suppliers, distributors and manufacturers; •internal and external costs associated with manufacturing our products and the impact on our cost of sales, and our anticipatedcost of sales as a percentage of net product sales; •the scope of protection we are able to establish and maintain for intellectual property rights, including those covering ourcommercial products, product candidates and technology, and our expectations regarding pending legal proceedings related to ourintellectual property; •the timing of initiation, progress, completion, results and cost of our clinical trials, preclinical studies and research anddevelopment programs, as well as those of our collaborators; •potential advantages of mRNA as compared to traditional medicine; •the implementation of our business model and strategic plans for our business, products, product candidates and technology; •the pricing and reimbursement of our products, if approved; •the build out of our manufacturing and commercial operations; •estimates of our future expenses, revenues and capital requirements; •our operation and funding requirements, including our forecast of the period of time through which our financial resources will be •the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or otheragreements with collaborators with development, regulatory and commercialization expertise; •our financial performance; •our tax positions and related tax liabilities; •legal and regulatory developments in the United States and foreign countries; •our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; and •developments relating to our competitors and our industry. Forward-looking statements often contain words such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,”“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparableterminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected inthese forward-looking statements are reasonable, these statements relate to future events or our operational or financial performance,and involve risks, uncertainties, and other factors that may cause our actual results to differ materially from any future resultsexpressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these forward-lookingstatements. Factors that may cause actual results to differ materially from current expectations include, among other things, those The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We undertake no obligation toupdate any forward-looking statements, except as required by applicable securities law. You should